Next Article in Journal / Special Issue
IMGT® and 30 Years of Immunoinformatics Insight in Antibody V and C Domain Structure and Function
Previous Article in Journal
Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases
Previous Article in Special Issue
IgG Charge: Practical and Biological Implications
Open AccessReview

David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments

Biopharm Molecular Discovery, GlaxoSmithKline, Hertfordshire SG1 2NY, UK
*
Author to whom correspondence should be addressed.
Antibodies 2019, 8(2), 28; https://doi.org/10.3390/antib8020028
Received: 1 February 2019 / Revised: 12 March 2019 / Accepted: 2 April 2019 / Published: 9 April 2019
(This article belongs to the Special Issue Structure and Function of Antibodies)
Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies have become the largest class of biopharmaceuticals with over 80 antibodies currently approved for a variety of disease indications. The development of smaller, antigen binding antibody fragments, derived from conventional antibodies or produced recombinantly, has been growing at a fast pace. Antibody fragments can be used on their own or linked to other molecules to generate numerous possibilities for bispecific, multi-specific, multimeric, or multifunctional molecules, and to achieve a variety of biological effects. They offer several advantages over full-length monoclonal antibodies, particularly a lower cost of goods, and because of their small size they can penetrate tissues, access challenging epitopes, and have potentially reduced immunogenicity. In this review, we will discuss the structure, production, and mechanism of action of EMA/FDA-approved fragments and of those in clinical and pre-clinical development. We will also discuss current topics of interest surrounding the potential use of antibody fragments for intracellular targeting and blood–brain barrier (BBB) penetration. View Full-Text
Keywords: ADC; antibody fragments; BiTE®; diabodies; domain antibodies; fab; ImmTAC®; Nanobody®; scFv; TandAb; V-NAR ADC; antibody fragments; BiTE®; diabodies; domain antibodies; fab; ImmTAC®; Nanobody®; scFv; TandAb; V-NAR
Show Figures

Figure 1

MDPI and ACS Style

Bates, A.; Power, C.A. David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments. Antibodies 2019, 8, 28.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop